Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas.
J Neuroendocrinol
; 35(5): e13283, 2023 05.
Article
in En
| MEDLINE
| ID: mdl-37229903
ABSTRACT
Poorly differentiated extrapulmonary neuroendocrine carcinomas (EP NECs) are aggressive cancers characterized by a high Ki-67 index, rapid tumor growth and poor survival, and are subdivided into small and large cell carcinoma. For small cell carcinoma of the lung, a pulmonary NEC, the combination of cytotoxic chemotherapy (CTX) and a checkpoint inhibitor (CPI) is considered standard therapy and superior to CTX alone. EP NECs are typically treated with platinum-based regimens, some clinicians have adopted the addition of a CPI to CTX based on data from trials in patients with small cell carcinoma of the lung. In this retrospective study of EP NECs, we report 38 patients treated with standard first-line CTX and 19 patients treated with CTX plus CPI. We did not observe any additional benefit of adding CPI to CTX in this cohort.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neuroendocrine Tumors
/
Carcinoma, Small Cell
/
Carcinoma, Neuroendocrine
Type of study:
Observational_studies
Limits:
Humans
Language:
En
Journal:
J Neuroendocrinol
Journal subject:
ENDOCRINOLOGIA
/
NEUROLOGIA
Year:
2023
Document type:
Article
Affiliation country:
Estados Unidos